Introduction
Exit opportunities from restructuring are among the most distinctive and concentrated in investment banking. While M&A coverage analysts can move into virtually any private equity firm, Rx analysts have a more specialized but equally lucrative exit landscape. The natural pathway is into distressed credit hedge funds and special situations private equity firms, where Rx-trained analysts arrive with technical skills that match the buy-side work directly. The pathways exist because the analytical work that Rx bankers do (capital structure analysis, recovery waterfalls, valuation under distress, claims trading dynamics) is structurally identical to the work that distressed funds perform daily.
This article walks through:
- the major exit pathways for Rx analysts and associates
- the firms that dominate each pathway
- the recruiting timeline
- what differentiates Rx exits from M&A exits
The Six Major Exit Pathways
Restructuring analysts have six distinct exit pathways, each with its own dominant firms, recruiting cycle, and compensation structure.
| Pathway | Description | Typical Compensation | Most Common Timing |
|---|---|---|---|
| Distressed credit hedge funds | Public debt and equity in distressed companies | $300-$500K total | After 2-3 years analyst |
| Special situations PE | Control and minority distressed equity | $300-$450K total | After 2-3 years analyst |
| Direct lending / private credit | Senior debt to mid-market companies | $250-$400K total | After 2-3 years analyst |
| M&A coverage / lateral IB | M&A or restructuring at peer firm | $220-$320K total | After 1-2 years (lateral) |
| Turnaround consulting | Operational restructuring (FTI, AlixPartners) | $200-$350K total | After 1-3 years |
| Corporate development | In-house at strategic acquirer or distressed entity | $200-$300K total | After 2-4 years |
The first two pathways (distressed credit hedge funds and special situations PE) capture the majority of Rx analyst exits at top firms. Among analysts who leave PJT, Houlihan Lokey, Evercore, Lazard, and Moelis for the buy side, these two destinations are the default landing spots, with private credit a fast-growing third. The compensation figures in the table are indicative ranges for first-year exit roles and vary widely by fund size and performance.
Distressed Credit Hedge Funds: The Most Common Exit
Distressed credit hedge funds invest in the debt and equity of companies in or near financial distress, typically aiming for substantial returns through workout situations, restructuring outcomes, and post-emergence equity. The work involves deep analytical engagement with capital structures, recovery scenarios, claims trading, and process dynamics. Restructuring bankers' day-to-day analytical work is essentially identical to what these funds do, which is why the exit pathway is so well-established.
The major distressed credit hedge funds include:
- Apollo Global Management. One of the largest distressed and credit investors globally, with multi-billion-dollar dedicated distressed strategies. Apollo's Hybrid Value Fund, distressed credit funds, and special situations strategies all recruit heavily from Rx backgrounds.
- Oaktree Capital Management. Co-founded in 1995 by Howard Marks and Bruce Karsh, Oaktree is the most senior name in distressed investing. The firm runs its flagship Opportunistic Credit strategy (the Opportunities funds) alongside Special Situations funds, and recruits analysts and associates from PJT, Houlihan Lokey, and Lazard with high frequency.
- Anchorage Capital Group. Once a marquee distressed hedge fund, Anchorage closed its $7.4 billion flagship fund in December 2021 and now concentrates on structured credit and longer-lockup credit funds. It still hires selectively for credit investing roles, but in far smaller numbers than a decade ago.
- GoldenTree Asset Management. Manages more than $70 billion across its credit platform, spanning high yield, leveraged loans, structured credit, distressed debt, and private credit. GoldenTree recruits Rx analysts for analyst and associate-level investment roles.
- Silver Point Capital. Distressed-focused multi-strategy fund. Strong reputation among Rx alumni; selective hiring.
- Centerbridge Partners. Combines distressed credit and private equity strategies. Centerbridge is among the most desirable destinations for Rx analysts because it combines hedge fund-style analytical work with PE-style control investments.
- Sculptor Capital. Owned by Rithm Capital since November 2023, Sculptor runs multi-strategy and credit funds that include opportunistic and distressed credit. Recruits selectively.
- Marathon Asset Management. A US credit manager with asset-based, opportunistic, and public credit strategies. CVC completed its acquisition of Marathon in July 2026, and the business now operates as CVC-Marathon.
Recruiting timing splits by fund type. Large credit platforms with distressed and special situations arms (Apollo, Ares, Blackstone, KKR) hire alongside buyout PE in the on-cycle process, extending offers 18-24 months before the start date; the 2027 associate class was recruited in January 2026, when most candidates were only six or seven months into their analyst programs. Smaller distressed hedge funds more often hire off-cycle, when a seat opens, which favors analysts in their second or third year who can start within a few months.
Special Situations Private Equity
Special situations PE firms invest in distressed companies through control and minority equity stakes, typically with operational improvement theses combined with capital structure rebuilds. The analytical work overlaps significantly with traditional buyout PE but the deal sourcing, structuring, and execution dynamics are different.
- Special Situations Investing
A flexible strategy that buys debt, preferred equity, or control stakes in companies facing a dislocation (a liquidity squeeze, covenant breach, Chapter 11, or forced sale), aiming to profit from the restructuring outcome rather than from steady operating growth.
What separates these firms from buyout shops is the entry point: they often take control through the capital structure, by buying the fulcrum debt and converting it to equity in a reorganization, rather than through an auction.
The major special situations PE firms include:
- Apollo Hybrid Value Fund and dedicated distressed strategies
- Oaktree Special Situations Fund (Fund IV held a record $2.4 billion first close in February 2026, with roughly $5 billion expected at final close)
- Centerbridge Partners distressed/PE platform
- Cerberus Capital Management
- Brookfield Special Investments
- Blackstone Tactical Opportunities (BX TacOpps)
- KKR Special Situations
- Ares Special Opportunities Fund (closed ASOF II at $7.1 billion in October 2022)
Operationally-focused PE firms with restructuring DNA include:
- Golden Gate Capital
- Platinum Equity
- Marlin Equity Partners
- Gores Group
- KPS Capital Partners
- Sun Capital Partners
These firms specialize in carve-outs, distressed acquisitions, and turnarounds where Rx-trained analysts add immediate value.
Direct Lending and Private Credit
Direct lending and private credit firms have grown dramatically in 2024-2025 as a destination for Rx analysts. The work involves underwriting senior debt to middle-market companies, often with restructuring optionality if borrowers run into trouble. Rx-trained analysts arrive with strong capital structure knowledge that translates directly into private credit underwriting.
The major direct lending platforms include Ares, Apollo Direct Lending, Blackstone Credit & Insurance, KKR Credit, Blue Owl (formerly Owl Rock), Antares Capital, Golub Capital, and HPS Investment Partners, which has been part of BlackRock since July 1, 2025. The consolidation matters for candidates: private credit seats increasingly sit inside large multi-asset managers rather than standalone credit shops. Compensation runs $250-$400K at the analyst level, slightly below distressed credit and special situations PE but with potentially better lifestyle.
M&A Coverage and Lateral IB
Some Rx analysts move laterally into M&A coverage or restructuring at a peer IB firm. The motivations vary: better cultural fit, specific sector interest, or strategic positioning for a different exit pathway.
Common lateral moves include PJT to Centerview (for prestige M&A exposure), Houlihan Lokey to Evercore or PJT (for higher prestige), and Lazard to specialized sector groups at peer firms. Lateral compensation typically tracks the new firm's standard grid, with modest premiums for exceptional performance.
Turnaround Consulting
Turnaround consulting firms (FTI Consulting, AlixPartners, Berkeley Research Group, Alvarez & Marsal) recruit Rx analysts for operational restructuring roles. The work involves embedded engagement with distressed companies as interim management, financial advisor on operational matters, or specialty advisor on specific restructuring questions.
Turnaround consulting offers different career trajectories than buy-side exits. The work is more operational and less financial; the lifestyle is often more travel-intensive but with more predictable hours; the compensation is typically lower than buy-side exits but with strong benefits packages. Some Rx analysts who want to deepen their operational expertise before moving to buy-side or operating roles use turnaround consulting as an intermediate step.
Corporate Development and In-House Roles
Some Rx analysts exit into corporate development at strategic acquirers or in-house roles at companies that have been through restructuring or are positioning for distressed acquisitions. Common destinations include private equity portfolio company operations, sponsor portfolio company CFO or VP Finance roles, and corporate development at industrial conglomerates.
The compensation runs $200-$300K total at the analyst exit level, lower than buy-side roles but with substantially better lifestyle (typically 50-60 hours per week) and direct operational exposure.
What Differentiates Rx Exits from M&A Exits
Restructuring exits differ from M&A exits in several specific ways:
| Dimension | Rx Exits | M&A Exits |
|---|---|---|
| Most common buy-side destination | Distressed credit hedge funds | Buyout PE |
| Recruiting cycle | Mix of on-cycle (large credit platforms) and off-cycle (hedge funds) | Mostly on-cycle (buyout PE) |
| Typical buy-side compensation premium | Smaller | Larger |
| Sector concentration | Broad (any distressed industry) | Sector-specific |
| Skill set transferability | Direct (capital structure analysis) | Direct (LBO, M&A modeling) |
| Long-term trajectory | Distressed specialist or generalist | Buyout PE or strategic operating |
The skill-set row cuts in one direction more than the other. Rx analysts regularly win buyout PE seats because recovery and capital structure work sits on top of standard LBO modeling, while M&A analysts without restructuring experience often struggle to clear a distressed fund's case study.
The Recruiting Process for Buy-Side Exits
Understanding the recruiting process for distressed credit hedge funds and special situations PE is critical because it differs substantially from traditional buyout PE recruiting.
- On-Cycle Recruiting
The compressed, headhunter-run process in which large private equity and credit firms interview first-year investment banking analysts and extend offers for associate roles that start 18-24 months later. Off-cycle recruiting, by contrast, fills individual seats as they open, with start dates a few months out.
Most Rx candidates effectively run both tracks: on-cycle for the large credit and special situations platforms, and off-cycle for hedge funds and smaller distressed shops. The sequence below shows how a typical process unfolds.
Pre-recruiting positioning (months 1-6 of analyst program)
Build technical skills, push for substantive deal exposure, identify target funds, and start conversations with alumni at target firms.
Headhunter engagement (months 4-8)
Connect with the major buy-side recruiters (Henkel Search Partners, Amity Search, Dynamic Search Partners, CPI). The headhunters control most introductions to the larger distressed and special situations platforms.
Initial fund outreach (on-cycle months 6-9; off-cycle months 12-30)
Funds reach out through headhunters, typically with a brief phone screen followed by case studies or modeling tests. On-cycle compresses the whole process into days; off-cycle processes run over weeks.
Case studies and modeling tests
Distressed credit interviews often include extensive case studies on specific distressed companies, with candidates expected to build recovery waterfalls, identify the fulcrum security, and value the post-emergence equity. Tests can run 4-8 hours each.
Final round
Multiple interviews with portfolio managers and investment team members. Cultural fit is critical at this stage; technical preparation is assumed.
Offer and acceptance
On-cycle offers often carry very short response windows; off-cycle offers more typically allow a week or two. Compensation negotiation is more bespoke than corporate IB compensation, with bonus structures and equity participation varying by fund.
Transition timing (months 24-36)
On-cycle hires usually start after completing two years of banking; off-cycle hires typically start within a few months of accepting, and some funds push strong candidates to move earlier.
The headhunter dimension is particularly important. Most top distressed credit and special situations PE seats fill through a small set of recruiting firms that maintain relationships with both candidates and funds. Candidates who do not engage with headhunters early in their analyst tenure often find that the best on-cycle opportunities have closed by the time they begin recruiting actively.
Compensation in Buy-Side Roles
Compensation at the typical Rx exit destinations runs higher than IB compensation but with more variability. Understanding the structure helps candidates evaluate offers comprehensively.
| Role | Year 1 Total Comp | Year 2 Total Comp | Year 3+ Total Comp |
|---|---|---|---|
| Distressed credit hedge fund analyst | $300-$500K | $400-$700K | $500K-$1M+ |
| Special situations PE associate | $300-$450K | $400-$600K | $500-$800K |
| Direct lending / private credit | $250-$400K | $300-$500K | $400-$700K |
| Buyout PE associate (M&A path) | $350-$500K | $450-$650K | $550-$800K |
| Turnaround consulting senior | $200-$350K | $250-$400K | $300-$500K |
Several patterns are worth noting:
- Bonus dispersion is wider at buy-side than at IB. A top performer at a distressed credit fund can earn $200-$300K more than a middle performer at the same fund, versus a roughly $50-$100K spread at typical IB analyst levels.
- Carry interest matters. Senior buy-side professionals (typically Year 3+ at top funds) begin to participate in carried interest, which can produce step-function increases in compensation. A $2 billion fund that doubles its capital generates $2 billion of profit and, at a standard 20% carry, a $400 million carry pool; a 2.5% share of that pool is worth $10 million over the fund life, dwarfing base compensation. The carry economics are why Rx analysts consider buy-side exits even at modest first-year compensation premiums versus banking.
- Tax efficiency improves at buy-side. Carried interest is typically taxed at long-term capital gains rates (a top federal rate of 20%, versus 37% on ordinary income) rather than as salary, provided the underlying investments are held for more than three years under Section 1061 of the Internal Revenue Code. That rate gap only applies to the carry portion of pay, so it matters most at senior, carry-eligible levels.
What Buy-Side Funds Look For in Rx Hires
The major distressed credit and special situations PE funds look for specific attributes in Rx analysts that are worth understanding for both interview prep and on-the-job positioning during the banking program:
- Strong technical fundamentals. Funds expect candidates to be comfortable with capital structure analysis, recovery waterfalls, fulcrum security identification, and DCF/comparable companies valuation under distressed conditions. The technical bar is high but not unattainable for analysts who have engaged seriously with their banking work.
- Specific deal experience. Funds favor candidates who have worked on at least 2-3 substantive Rx mandates with meaningful analytical contribution. A candidate who staffed primarily on pitches without deep deal exposure may struggle in interviews even with strong academic credentials.
- Investment thinking. Distressed funds want candidates who can articulate investment theses, not just describe deal mechanics. The ability to say "if I were investing in this company today, I would buy the unsecured bonds at 40 cents because..." separates buy-side-ready candidates from candidates who are still thinking like advisors.
- Cultural fit. Distressed funds tend to be smaller (often 30-100 investment professionals) and culture matters more than at large IB firms. Funds look for candidates who will fit specific team dynamics, contribute to investment debates, and bring the right level of intellectual aggressiveness.
- Long-term commitment. Most distressed credit funds want analysts who will stay 5-10 years rather than treat the role as a stepping stone to PE or other paths. Candidates who signal strong interest specifically in distressed credit fund work do better than candidates who treat distressed credit as one of several options.
Long-Term Career Trajectories
Looking at Rx analyst alumni trajectories ten to twenty years out, several common paths emerge:
- Distressed credit hedge fund partner. Analyst at PJT/HL/Evercore → analyst at Apollo/Oaktree → senior analyst → portfolio manager → fund partner.
- Special situations PE partner. Analyst at PJT/Centerview → senior associate at Centerbridge → principal → MD or partner.
- Distressed credit fund founder. Analyst at top Rx firm → senior role at established fund → spin out to start own fund.
- Senior Rx banker. Analyst → associate → VP → MD at a major Rx firm. Less common as a long-term path because of the appeal of buy-side exits.
- Operating role. Analyst → distressed PE associate → portfolio company executive role → CEO or CFO.
- Other paths. Some Rx alumni pursue policy roles (Treasury, FDIC), academic or teaching positions, or alternative finance careers.
The Rx-to-distressed-credit-hedge-fund pathway is among the most lucrative on Wall Street. Senior portfolio managers at successful distressed credit funds can earn multi-million-dollar annual payouts, and top performers reach far higher in strong distressed cycles when carry and performance fees crystallize. The path requires strong analytical fundamentals, substantial industry experience, and a willingness to take meaningful career risk; the rewards justify the path for candidates who fit. The next nine articles in this section go deeper into the Rx career path, from the two main buy-side exits and lateral moves into M&A to interview preparation; for how candidates break into restructuring in the first place, see recruiting for restructuring.
